- Lung cancer therapy including novel compounds and early phase trials
- Breast cancer therapeutics including novel compounds and early phase trials
- Health services research
- Economics of lung cancer therapy
- Treatment decision-making in advanced cancer, including development of patient decision aids
- Patient-physician communication
Natasha B Leighl
Expert Rev Respir Med. 2017 Nov 30;:
Adjuvant chemotherapy with or without bevacizumab in patients with resected non-small-cell lung cancer (E1505): an open-label, multicentre, randomised, phase 3 trial.
Lancet Oncol. 2017 Nov 09;:
Genome-wide interaction study of smoking behavior and non-small cell lung cancer risk in Caucasian population.
Carcinogenesis. 2017 Oct 20;:
Participant selection for lung cancer screening by risk modelling (the Pan-Canadian Early Detection of Lung Cancer [PanCan] study): a single-arm, prospective study.
Lancet Oncol. 2017 Oct 16;:
A phase I study of foretinib plus erlotinib in patients with previously treated advanced non-small cell lung cancer: Canadian cancer trials group IND.196.
Oncotarget. 2017 Sep 19;8(41):69651-69662
Case for Stopping Targeted Therapy When Lung Cancer Progresses on Treatment in Hospice-Eligible Patients.
J Oncol Pract. 2017 Oct 05;:JOP2017027367
Biomarker analysis of the phase 3 TORCH trial for first line erlotinib versus chemotherapy in advanced non-small cell lung cancer patients.
Oncotarget. 2017 Aug 22;8(34):57528-57536
Nintedanib Plus Pemetrexed/Cisplatin in Patients With Malignant Pleural Mesothelioma: Phase II Results From the Randomized, Placebo-Controlled LUME-Meso Trial.
J Clin Oncol. 2017 Sep 11;:JCO2017729012
Economic Considerations in the Use of Novel Targeted Therapies for Lung Cancer: Review of Current Literature.
Pharmacoeconomics. 2017 Aug 31;:
Prognostic and predictive effects of TP53 co-mutation in patients with EGFR-mutated non-small cell lung cancer (NSCLC).
Lung Cancer. 2017 Sep;111:23-29
Cancer Clinical Research Unit (CCRU), Princess Margaret Cancer Centre
Associate Professor, Department of Medicine, University of Toronto
President, Lung Cancer Canada
Chair, Working Group on Economic Analysis, National Cancer Institute of Canada Clinical Trials Group